'Pharmaceutical Contract Sales Market Will Reach $3,912m in 2013' Predicts new Visiongain Report

LONDON, November 13, 2012 /PRNewswire/ --

A new report by visiongain predicts that the global market for pharmaceutical contract sales will be worth $3,912m in 2013. Between 2011 and 2017, the worldwide market will grow with a CAGR of over 8%. Demand for outsourced sales teams will drive growth during this decade. Those findings and others appear in World Pharmaceutical Contract Sales Market 2013-2023, published in November 2012. Visiongain is a business information provider based in London, UK.

Personal promotion will account for the largest proportion of pharma contract sales organisation (CSO) revenues throughout the 10-year forecast period. However, faster growth will come from other sectors of the contract sales market. Outsourcing of non-personal promotion will increase from 2012 to 2023, driven in the early years by greater use of teledetailing. Innovation and improvements to current technology will provide greater opportunities for virtual detailing. In 2023, outsourced edetailing will account for close to $200m in CSO revenues, the report shows.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Pharmaceutical sales models are changing rapidly. Healthcare payers have greater influence in prescribing decisions, complicating market access strategies for pharmaceutical companies. CSOs are expanding beyond traditional sales services to meet demand for market access expertise from pharmaceutical partners. Add-on services, such as medical education and patient compliance, will offer new sources of revenue for CSOs in the period 2013-2023.

"Our study forecasts the leading national pharmaceutical contract sales markets. In 2011, the US and Europe dominated the market, accounting for more than 75% of global revenues. However, market leaders, such as inVentiv Health, Quintiles and United Drug, already operate on a global scale. Recently these companies made advances into emerging markets, establishing offices in the BRIC nations (Brazil, Russia, India and China). Drug developers are increasingly interested in entering emerging markets, looking to take advantage of expanding healthcare coverage, rising wealth, and large patient populations. Outsourcing will provide local expertise in market access and sales models. Fast growth is forecast for all four of the BRIC nations, in terms of contract sales, to 2023."

World Pharmaceutical Contract Sales Market 2013-2023 provides original quantitative and qualitative analyses of the pharma contract sales market. It shows revenue forecasts to 2023 for the overall world market, submarkets and prominent national markets. It also identifies and discusses future trends likely to affect that industry and market. The study adds to visiongain's portfolio of analytical reports covering pharmaceutical outsourcing and service markets.

For further information concerning Visiongain's World Pharmaceutical Contract Sales Market 2013-2023 report please visit http://www.visiongain.com/Report/928/World-Pharmaceutical-Contract-Sales-Market-2013-2023

Contact: Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Companies Listed
360 Vantage
Abbott Laboratories
Across Health
Actelion Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA)
Akcess
Akrikhin
Allergan
Alliance Healthcare (part of United Drug)
Almirall
Apple
Ashfield Healthcare Ireland (part of United Drug)
Ashfield Healthcare (part of United Drug)
Ashfield In2Focus (part of United Drug)
Ashfield KK (part of United Drug)
Association of the British Pharmaceutical Industry (ABPI)
Astellas Pharma
AstraZeneca
Biogaran
Blue Diesel (part of inVentiv Health)
Boehringer Ingelheim
Ministério da Saúde [Brazil]
Business Edge Solutions and Training (BEST)
Cegedim Strategic Data
Celesio
Centers of Medicare and Medicaid Services (CMS) [US]
Chinese Ministry of Health
Cider Sante (part of Pharmexx)
CMIC
CMIC MPSS Co (part of CMIC)
CMR Institute [US]
Congressional Budget Office (CBO) [US]
Consumer Advisory Group [UK]
Corcept Therapeutics
Daiichi Sankyo
Dayarn Pharma
Delcath Systems
Depomed
Drug Safety Alliance (DSA, part of United Drug)
Eisai
Eli Lilly
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Evolve Selection
Federation of Medical Representatives Association of India (FMRAI)
Ferring Pharmaceuticals
Food and Drug Administration (FDA) [US]
Genentech (part of Roche)
Go! Healthcare Marketing
Grey Healthcare Group
Group DCA (part of PDI)
Grünenthal
GSK
Health Kare Pharma International (HKPI)
Human Genome Sciences (part of GSK)
IMS Health
Informed Medical Communications
Innovex (part of Quintiles)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG) [Germany]
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Interpace BioPharma (part of PDI)
inVentiv Health
inVentiv Health Korea (part of inVentiv Health)
inVentiv Health Selling Solutions (part of inVentiv Health)
inVentiv Japan (part of inVentiv Health)
inVentiv Recruitment Services (part of inVentiv Health)
inVentiv Therapeutics Institute (part of inVentiv Health)
Invida
Iroko Cardio International
Japan Contract Sales Organisation Association (JCSOA)
Japan Pharmaceutical Manufacturers Association (JPMA)
Kadrige
Les enterprises du médicament (LEEM) [France]
Leo Pharma
LG
Lupin Pharmaceuticals
Marvecs
MDS Co (part of CMIC)
MELA Sciences
Menarini Group
Merck & Co.
Merqurio Group
Merqurio Pharma
Ministerio de Sanidad, Servicios Sociales e Igualdad [Spain]
Motorola
MySTRO (part of inVentiv Health)
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
NATIVE
NetworksMD/Pharmalink (part of Zuellig Pharma)
Neurocrine Biosciences
Novartis
Nycomed
OnCall
Oracle
Organisation of Pharmaceutical Producers of India (OPPI)
PDI
PDI Voice (part of PDI)
Pfizer
Pharco Pharmaceuticals
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmakon
Pharmartis
Pharmexx (part of United Drug)
Polpharma
Proton Pharma
Publicis Healthcare Communications Group
Publicis Touchpoint Solutions
Q.E.D. International (part of Quintiles)
Qforma
Quintiles
Ramco Import Export
Research in Motion (RIM)
Roche
Rottapharm Madaus
Samsung
Sanofi
Santarus
Scottish Medicines Consortium (SMC)
Sermo
Servier
Shalaks Pharmaceuticals (part of Invida)
Sinclair IS Pharma
Sofip
Stallergenes
StayinFront
Synopia Rx (part of United Drug)
Temas
Temasek Holdings
The Royce Consultancy (part of Quintiles)
Thomas H. Lee Partners
Touchpoint Recruiting Solutions
United Drug
Universal WorldEvents
Valeritas
VCG Bio
VCG & Associates
Veeva Systems
Vivus
WPP
Zuellig Group
Zuellig Pharma 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100